NYSE:NUVB Nuvation Bio Q3 2024 Earnings Results & Report $4.72 -0.18 (-3.57%) Closing price 03:59 PM EasternExtended Trading$4.73 +0.01 (+0.13%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Nuvation Bio missed analyst earnings expectations in its Q3 2024 results, released November 6, 2024. The company reported EPS of -$0.15 versus the -$0.13 consensus estimate, while revenue was $0.73 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 6, 2024TimeAfter Market ClosesConference Call DateNovember 5, 2024Conference Call6:00 PM ET Nuvation Bio EPS ResultsActual EPS-$0.15Consensus EPS -$0.13Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersNuvation Bio Revenue ResultsActual Revenue$0.73 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNuvation Bio's Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nuvation Bio Q3 2024 Earnings FAQ Did Nuvation Bio beat earnings estimates for Q3 2024? Nuvation Bio (NYSE:NUVB) reported earnings of -$0.15 per share for Q3 2024, missing the consensus estimate of -$0.13. The report was announced on Wednesday, November 6, 2024. What was Nuvation Bio's revenue for Q3 2024? Nuvation Bio reported revenue of $0.73 million for Q3 2024. When is Nuvation Bio's next earnings date? Nuvation Bio's next earnings date is estimated for Monday, November 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Nuvation Bio on the company's earnings history page. Nuvation Bio Earnings HeadlinesLyell Immunopharma (NASDAQ:LYEL) versus Nuvation Bio (NYSE:NUVB) Financial AnalysisOctober 12 at 3:58 AM | americanbankingnews.comNuvation Bio (NYSE:NUVB) Stock Gets Downgrade from Wall Street ZenOctober 10 at 1:37 AM | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 13 at 1:00 AM | Chaikin Analytics (Ad)Contrasting Nuvation Bio (NYSE:NUVB) & Janux Therapeutics (NASDAQ:JANX)October 3, 2026 | americanbankingnews.comCitigroup initiates coverage of Nuvation Bio with buyOctober 1, 2026 | msn.comCitigroup Initiates Nuvation Bio at Buy With $12 Price TargetSeptember 30, 2026 | marketscreener.comMSee More Nuvation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email. Email Address About Nuvation BioNuvation Bio (NYSE:NUVB), Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses small-molecule drug discovery and development approaches to pursue therapies intended to address difficult-to-treat tumors and areas of significant unmet medical need. Nuvation Bio’s pipeline has included NUV-868, an oral investigational inhibitor of DYRK1A being studied in solid tumors, and NUV-1511, an investigational oncology drug designed to interfere with cancer-cell DNA damage response mechanisms. The company has also expanded its development capabilities through the acquisition of AnHeart Therapeutics, adding radiopharmaceutical research and development programs to its broader oncology portfolio. Nuvation Bio was founded by David Hung, M.D., who serves as the company’s founder, president and chief executive officer. The company became a publicly traded business in 2021 and is headquartered in the United States, where it conducts its research and development activities in collaboration with clinical and scientific partners.View Nuvation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
